Alx Oncology  logo
ALXOAlx Oncology 
Trade ALXO now
Alx Oncology  primary media

About Alx Oncology 

Alx Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology firm focused on developing therapies for patients battling cancer. It leverages its expertise in CD47 blockade to create treatments that aim to enhance the body's immune response against tumors. The company has multiple projects in the pipeline, including lead candidate ALX148, designed for a variety of hematologic and solid malignancies. Alx Oncology's goal is to develop innovative, effective cancer treatments that improve patient outcomes across the globe. Through strategic collaborations and cutting-edge research, it strives to unlock new possibilities in cancer therapy, advancing towards key clinical milestones.

What is ALXO known for?

Snapshot

Public US
Ownership
2015
Year founded
78
Employees
California, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Alx Oncology 

  • ASPEN-03: This clinical trial investigates the combination of ALX148 (their investigational drug) with pembrolizumab (Keytruda) for the treatment of advanced head and neck squamous cell carcinoma (HNSCC) in patients with PD-L1 expressing tumors.
  • ASPEN-04: This clinical trial explores the effectiveness of combining ALX148 with pembrolizumab (Keytruda) and standard chemotherapy for treating advanced HNSCC in patients who haven't received prior treatment.
  • ASPEN-06: This trial focuses on evaluating the potential of ALX148 (also known as Evorpacept) as a single agent in treating advanced HER2-positive gastric cancer.
  • ASPEN-07: This trial investigates the combination of ALX148 (Evorpacept) with enfortumab vedotin for the treatment of subjects with urothelial carcinoma.

Alx Oncology  executive team

  • Mr. Jason W. LettmannCEO & Director
  • Ms. Shelly Pinto CPASenior VP of Finance & Chief Accounting Officer
  • Mr. Harish Shantharam C.F.A.Chief Financial Officer
  • Dr. Athanasios Tsiatis M.D.Senior Vice President of Clinical Development
  • Dr. Lin Yeong-Liang M.D., M.S.Senior Vice President of Drug Safety & Pharmacovigilance
  • Ms. Lisa SauerSenior Vice President of Regulatory Affairs & Quality Assurance
  • Ms. Sue NaimSenior Vice President of Clinical Operations
  • Ms. Venita De Almeida Ph.D.VP & Head of Research Program Development
  • Dr. Barbara J. Klencke M.D.Interim Chief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.